09 August 2024
09 August 2024
Exscientia shareholders will receive 0.7729 shares of Recursion class A common stock for each share held.
The gene editing therapy will now be accessible to NHS England patients with beta-thalassemia, potentially replacing lifelong transfusions.
The company insists that it is producing the device US-wide at no profit to itself while continuing the production of its nalmefene hydrochloride injection in single-dose vials.
The contract will see bulk product for Jynneos replenished and additional services for dose storage.
Total revenue for Q2 increased by 5% to $6.95bn and operating cash flow stood at $1.3bn.
Conduit plans to advance two assets, AZD1656 and AZD5658, into Phase II testing for autoimmune disorders.
Pharmacosmos will secure its second FDA-approved drug and first oncology therapy, G1 Therapeutics’ Costela as part of the merger.
The collaboration will combine Medigene's advanced TCR generation capabilities with WuXi Biologics' platform.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
